anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The objective of this study is to assess the impact of dietary intake and supplementation of total magnesium, iron, zinc and selenium on pulmonary function in middle-aged to elderly individuals diagnosed with chronic obstructive pulmonary disease (COPD). This study utilized publicly available data from NHANES, focusing on the 2007-2012 cycles to include participants aged 50 and above with COPD. The definition of COPD followed the 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Dietary mineral intake was assessed through two 24-h dietary recall surveys. Pulmonary function assessments included parameters such as forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), forced mid-expiratory flow (FEF 25-75%), and peak expiratory flow (PEF). Sex-specific associations of total magnesium, iron, zinc, and selenium intakes with pulmonary function parameters were assessed using multivariable regression models adjusted by potential covariates. The study sample had a mean age of 64.56 ± 8.26 years, with 35% being female. The median intakes of total magnesium, iron, zinc, and selenium for males were 312.8 mg, 15.6 mg, 14.4 mg, and 127.9 mcg, respectively, while for females, they were 257.5 mg, 12.8 mg, 11.4 mg, and 96.2 mcg. In males, higher total magnesium and iron intake were significantly associated with increased FEV1, FVC, and PEF (P < 0.05), while in females, only total zinc intake showed a positive association with PEF (P < 0.05). Participants meeting the recommended dietary allowance for total magnesium also exhibited significantly better lung function outcomes in both sexes. This study highlights the importance of adequate dietary mineral intake in managing pulmonary health among COPD patients. Enhancing mineral consumption, particularly magnesium, and iron, may be a viable strategy for improving lung function and overall health in this population, especially in men.
Interference with certain coagulation assays has been detected in patients treated with CIMZIA. Certolizumab pegol may cause erroneously elevated activated partial thromboplastin time (aPTT) assay results in patients without coagulation abnormalities. This effect has been observed with the PTT-Lupus Anticoagulant (LA) test and Standard Target Activated Partial Thromboplastin time (STA-PTT) Automate tests from Diagnostica Stago, and the HemosIL APTT-SP liquid and HemosIL lyophilized silica tests from Instrumentation Laboratories. Other aPTT assays may be affected as well. Interference with thrombin time (TT) and prothrombin time (PT) assays has not been observed. There is no evidence that CIMZIA therapy has an effect on in vivo coagulation.
Women were supplemented with apples. Sixteen women were asked to ingest three apple daily between meals ( approximately 120g kcal) between meals (breakfast, lunch and dinner).
OBJECTIVES: Nocturia is considered a clinical problem when nocturnal urinary frequency is two or more times. For affected patients, development of depression, falling, and increased mortality rate are matters of concern. The present study investigated the efficacy and safety of lemborexant for insomnia patients with nocturia.
METHODS: Insomnia patients (Athens Insomnia Scale [AIS] ≥ 6) who typically awoke twice or more during the night to urinate and were examined at our institutions from June 2021 to December 2022 were enrolled. Each was administrated 5 mg of lemborexant, one tablet, daily for 4 weeks. Total AIS score, nocturia frequency, individual frequency-volume chart findings, and N-QOL score were examined before and after administration.
RESULTS: Of the 37 patients recruited, 5 were excluded, thus 32 were enrolled and subjected to analyses. Following lemborexant therapy, the mean AIS total score was significantly decreased from 11.4 to 7.8 (p < 0.01) as was mean number of nocturia episodes from 3.4 to 2.3 (p < 0.001). Furthermore, the mean single voided urine volume at night was significantly increased from 182.5 to 225.3 mL (p < 0.001)and mean period of undisturbed sleep was significantly extended from 105.3 to 174.8 min (p < 0.001), while mean total N-QOL score was significantly improved from 49.6% to 64.8% (p < 0.001). As for adverse events, mild somnolence was observed in three cases.
CONCLUSIONS: Lemborexant may be effective and safe for use in insomniac patients with nocturia.
The invention relates to a traditional Chinese medicine decoction for emergently treating sunstroke faint. The traditional Chinese medicine decoction is prepared from the following raw materials in parts by weight: 10g to 30g of fresh reed rhizome juice, 10g to 30g of Chinese chive juice, 10g to 40g of fresh lotus root juice, 10g to 20g of ginger juice, 10g to 20g of bitter melon juice, 10g to 40g of pear juice and 10g to 50g of watermelon juice. The adopted raw materials are common in life; particularly, a large number of the raw materials are sold in the market at the season with a high sunstroke occurrence, so that the raw materials are simple, easy to obtain, low in cost as well as simple and convenient in preparation method. The traditional Chinese medicine decoction can be stored in a refrigerator for later use. When the traditional Chinese medicine decoction is used for treating 139 patients with the sunstroke faint, all the patients taking the traditional Chinese medicine decoction are waken up within 5 minutes, so that the effective rate of the traditional Chinese medicine decoction reaches 100%. The traditional Chinese medicine decoction is rapid in efficacy and good in treatment effect, and cannot generate toxic and side effects. In addition, the traditional Chinese medicine decoction can be taken by the patients with mild heatstroke.
Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
PCT No. PCT/JP90/01344 Sec. 371 Date Jun. 19, 1991 Sec. 102(e) Date Jun. 19, 1991 PCT Filed Oct. 10, 1990 PCT Pub. No. WO91/06005 PCT Pub. Date May 2, 1991.The present invention is concerned with a method of assaying D-vanillylmandelic acid (D-VMA) contained in a specimen of a living organism through the following steps (A) to (D), and a reagent and a kit used for the assay, wherein a racemic mixture of VMA is used as the standard substance for preparing a calibration curve and a labeled anti-D-VMA antibody is used as the labeled anti-VMA antibody to specifically assay only D-VMA in the specimen: (A) the step of conducting a competitive reaction of VMA in the specimen and VMA in solid phase against the labeled anti-VMA antibody; (B) the step of separating the liquid phase from the solid phase; (C) the step of determining the quantity of labeling of the labeled anti-VMA antibody combined with the solid-phase VMA and that of other substances; and (D) the step of preparing a calibration curve or obtaining an equation by using a standard substance of a known concentration, calculating the concentration of VMA corresponding to the quantity of labeling determined in the step (C) by using the calibration curve or equation thus obtained, and defining the concentration thus calculated as the concentration of VMA contained in the specimen.
BACKGROUND: Supravalvar aortic stenosis (SVAS) is a characteristic feature of Williams-Beuren syndrome (WBS). Its severity varies: ~20% of people with Williams-Beuren syndrome have SVAS requiring surgical intervention, whereas ~35% have no appreciable SVAS. The remaining individuals have SVAS of intermediate severity. Little is known about genetic modifiers that contribute to this variability.
METHODS AND RESULTS: We performed genome sequencing on 473 individuals with Williams-Beuren syndrome and developed strategies for modifier discovery in this rare disease population. Approaches include extreme phenotyping and nonsynonymous variant prioritization, followed by gene set enrichment and pathway-level association tests. We next used GTEx v8 and proteomic data sets to verify expression of candidate modifiers in relevant tissues. Finally, we evaluated overlap between the genes/pathways identified here and those ascertained through larger aortic disease/trait genome-wide association studies. We show that SVAS severity in Williams-Beuren syndrome is associated with increased frequency of common and rarer variants in matrisome and immune pathways. Two implicated matrisome genes (ACAN and LTBP4) were uniquely expressed in the aorta. Many genes in the identified pathways were previously reported in genome-wide association studies for aneurysm, bicuspid aortic valve, or aortic size.
CONCLUSIONS: Smaller sample sizes in rare disease studies necessitate new approaches to detect modifiers. Our strategies identified variation in matrisome and immune pathways that are associated with SVAS severity. These findings suggest that, like other aortopathies, SVAS may be influenced by the balance of synthesis and degradation of matrisome proteins. Leveraging multiomic data and results from larger aorta-focused genome-wide association studies may accelerate modifier discovery for rare aortopathies like SVAS.
On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
The present invention relates to obtaining a new agri-food product by macerating fruit in wine vinegar. The fruits studied are strawberries and citrus fruits, orange, lime, lemon and grapefruit. The maceration causes that the compounds of the fruits happen to the sine of the vinegar, increasing the concentration of polifenoles what provokes an increase of the antioxidant power, besides confererirles them attractive organoleptic properties. The optimization of the process has been established based on the content of polyphenolic compounds, ascorbic acid content and antioxidant power of the products obtained, as well as subjecting them to the organoleptic assessment by a panel of expert tasters. The proposed procedure has an easy and marked industrial application in the agri-food area, food technology and, specifically, in the wine sector. (Machine-translation by Google Translate, not legally binding)
The invention discloses traditional Chinese medicine unguent for treating skin diseases. The unguent is prepared from such medicinal raw materials as senecio scandens, radix arnebia/radix lithospermi, safflower carthamus and coptis chinensis. A preparation method of greasy traditional Chinese medicine unguent comprises the steps of heating and dissolving vaseline; adding the coptis chinensis, golden cypress and other ingredients to the vaseline for heating; after the color of the medicinal raw materials turns to be dark yellow, adding the senecio scandens, the safflower carthamus and the radix arnebia/radix lithospermi; after the vaseline is in aubergine, turning off flame, discarding dregs, lowering the temperature, adding borneol for dissolution, conducting cooling, and obtaining the greasy traditional Chinese medicine unguent. A preparation method of water-soluble traditional Chinese medicine unguent comprises the steps of making the medicinal raw materials into aqueous extraction liquid, and making the aqueous extraction liquid into the water-soluble traditional Chinese medicine unguent. The medicinal raw materials of the traditional Chinese medicine unguent are mainly capable of dispelling wind, removing dampness, clearing away heat and toxic materials, cooling the blood, discharging fire, eliminating swelling, promoting tissue regeneration, dispersing stasis and relieving pain. The traditional Chinese medicine unguent is remarkable in effect of treating such skin diseases as burns, scalds, mosquito bites, eczema, diaper rash, urticaria and skin itch. The traditional Chinese medicine unguent is prepared from pure traditional Chinese medicine, is scientific in composition, remarkable in treatment effectiveness, convenient to use, safe, reliable, free of toxic and side effects and can be used for treating multiple types of common skin diseases and serve as requisite medicine of a medicine-chest for a family or when a person goes out for travel.
FIELD: molecular biology, virology. SUBSTANCE: invention relates to recombinant adenoviral vectors of expression exhibiting the partial or complete deletion of adenovirus DNA fragment that encodes the protein IX and containing gene encoding the foreign protein or its functional fragment or mutant form. Invention proposes a pharmaceutical composition including recombinant adenoviral expression vector which has insertion of exogenous DNA with gene encoding the foreign protein and adenoviral DNA with deletion from initial position 357 to 360 and terminal position from 4020 to 4050. Indicated pharmaceutical composition can be used in genetic therapy, for transformation of hyperproliferated cells in mammals, cancer therapy, inhibition of tumor proliferation in animals, decrease of tumor cells proliferation. EFFECT: recombinant vector indicated above, valuable biological and medicinal properties. 20 cl, 40 dwg, 2 tbl, 3 ex
OBJECTIVE: Patients with coexisting spastic cerebral palsy (CP) and dystonia have limited treatment options. In this study, the authors aimed to evaluate the efficacy of deep brain stimulation (DBS) targeting the superior cerebellar peduncles (SCPs) in adults with CP.
METHODS: Five patients with CP and medically refractory dystonia and spasticity underwent SCP DBS. Assessments included the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), modified Ashworth scale (mAS), and tests of cognition, mental status, and quality of life preoperatively and at 3, 6, and 12 months postoperatively (in both DBS ON and OFF states, double blinded). Active contacts and fiber bundles were examined.
RESULTS: Four patients completed follow-up. The BFMDRS motor score decreased from 74 to 52 at 12 months postoperatively (30%, p = 0.008). The mean mAS score indicated significant spasticity reduction (from 2.9 ± 0.9 to 1.9 ± 0.6 after 12 months, p = 0.0454). Quality of life improved (p < 0.01), while cognition remained unaffected. Active contacts were found within the dentato-rubro-thalamic tract, with variable efficiency in decussating and nondecussating portions.
CONCLUSIONS: In this pilot trial, SCP DBS showed promise as a well-tolerated treatment for CP, improving dystonic symptoms, spasticity, quality of life, and functional capacities. However, caution is needed when interpreting the results given the small sample size and heterogeneous motor outcomes.
The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.
You will be asked to consume 5 grams of glutamine three times a day for 12 weeks. At week four, you will be asked to return to the CRC to be assessed, and then to return every four weeks until week 12, which will be the conclusion of the study.
BACKGROUND: Functional visual impairments in children are primarily caused by amblyopia or strabismus. This study aimed to determine the prevalence and clinical profile of amblyopia and strabismus among individuals aged 3-16 years in Shanghai, China.
METHODS: From February 2023 to February 2024, this hospital-based, cross-sectional study included data of children who visited the Ophthalmology Department of Shanghai General Hospital. Comprehensive ocular examinations included visual acuity measurement after cycloplegic refraction, slit lamp examination, cover test, and dilated fundus examination. Descriptive statistics were performed to estimate the proportion and clinical characteristics of amblyopia and strabismus.
RESULTS: A total of 920 children were enrolled in our study. Among them, 223 (24.24%) children were identified as amblyopia. Unilateral amblyopia occupied 57.85%, and bilateral amblyopia occupied 42.15%. Most participants were within the age range of 5-10 years (75.97% for unilateral amblyopia, and 70.21% for bilateral amblyopia). Anisometropia was the primary cause of unilateral amblyopia (68.99%). Most amblyopic children have high hyperopia (38.76% for unilateral amblyopia, and 39.89% for bilateral amblyopia). 30 (3.26%) children were diagnosed with strabismus, and 19 (63.3%) of them were aged 5-10 years. Seven of the children had both strabismus and amblyopia.
CONCLUSION: The proportion of patients with amblyopia and strabismus was determined as 24.24% and 3.26% in our study. Anisometropia was the leading cause of unilateral amblyopia, whereas high hyperopia was a crucial refractive error in the amblyopic population. These findings shed light on further longitudinal studies targeting the age-related changes in amblyopia, strabismus and refraction errors. Therefore, efforts should be made to manage uncorrected refractive errors, amblyopia, and strabismus among children in Shanghai.
Alterations in the gut-microbiome-brain axis are increasingly being recognized to be involved in Alzheimer's disease (AD) pathogenesis. However, the functional consequences of enteric dysbiosis linking gut microbiota and brain pathology in AD progression remain largely undetermined. The present work investigated the causal role of age-associated temporal decline in butyrate-producing bacteria and butyrate in the etiopathogenesis of AD. Longitudinal metagenomics, neuropathological, and memory analyses were performed in the 3×Tg-AD mouse model. Metataxonomic analyses showed a significant temporal decline in the alpha diversity marked by a decrease in butyrate-producing bacterial communities and a concurrent reduction in cecal butyrate production. Inferred metagenomics analysis identified the bacterial acetyl-CoA pathway as the main butyrate synthesis pathway impacted. Concomitantly, there was an age-associated decline in the transcriptionally permissive acetylation of histone 3 at lysines 9 and 14 (H3K9/K14-Ac) in hippocampal neurons. Importantly, these microbiome-gut-brain changes preceded AD-related neuropathology, including oxidative stress, tau hyperphosphorylation, memory deficits, and neuromuscular dysfunction, which manifest by 17-18 months. Initiation of oral administration of tributyrin, a butyrate prodrug, at 6 months of age mitigated the age-related decline in butyrate-producing bacteria, protected the H3K9/K14-Ac status, and attenuated the development of neuropathological and cognitive changes associated with AD pathogenesis. These data causally implicate age-associated decline in butyrate-producing bacteria as a key pathogenic feature of the microbiome-gut-brain axis affecting the onset and progression of AD. Importantly, the regulation of butyrate-producing bacteria and consequent butyrate synthesis could be a significant therapeutic strategy in the prevention and treatment of AD.
Insulin resistance in skeletal muscle is a characteristic abnormality in obesity and the metabolic syndrome and a major factor responsible for the development of type 2 diabetes. Although the mechanisms responsible for muscle insulin resistance are largely unclear, lipid oversupply is an important factor. Among numerous potential mechanisms whereby lipid oversupply may cause muscle insulin resistance, current evidence points towards inflammation as being critical. Recent studies in animals, however, indicate that the inflammatory response in skeletal muscles may require the presence of circulating pro-inflammatory factors suggesting that the inflammation induced insulin resistance in skeletal muscles may be a secondary event. More specifically, activation of Nuclear Factor-Kappa B(NF-kB), and inflammatory master switch that drives the production of numerous pro-inflammatory cytokines in fat and liver, has been implicated in causing insulin resistance in skeletal muscles by increasing circulating pro-inflammatory cytokines. In contrast, animal studies have found that activation of NF-KB directly in skeletal muscles has no or little effect on its insulin sensitivity but does produce other abnormalities such as increased proteasome activity. The study shall therefore be undertaken to determine to what extent lipid-induced inflammation and insulin resistance in skeletal muscles requires the presence of circulating proinflammatory factors in humans.
The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was for females randomized.
RCA-CRRT will be ordered based on clinical indications and will be performed according to a standardized protocol (available as online supplementary material) in continuous veno-venous hemofiltration mode with the same system (Prismaflex®; Gambro-Baxter, Deerfield, IL, USA) and a 0.9 m2 high-flux AN69 membrane. Blood flow will be maintained between 120 and 180 mL/min according to the patient's ideal body weight. The prescribed dose of filtration will be 30 mL/kg/h to achieve a delivered dose of 20-25 mL/kg/h, following KDIGO guidelines. A citrated replacement solution (Regiocit®; Gambro-Baxter), containing 18.0 mmol/L of citrate, will be delivered continuously to the blood before the filter of the extracorporeal circuit. The rate of infusion of predilution replacement flow will be coupled to the blood flow, aiming for a stable citrate concentration in the extracorporeal circuit. The initial citrate dose will be 3.0 mmol/L of blood, and then citrate flow rate will be adjusted to the post-filter iCa target according to the protocol. Post-filter iCa will be measured on ABL90 FLEX PLUS™ (Radiometer Medical©, Copenhagen, Denmark) blood gas analyzer 15 minutes after any change in dose and then every 6 hours. Calcium chloride will be administered to the patient through a central line to maintain systemic-iCa within 1.00-1.30 mmol/L. Fluid removal rates will be left to the discretion of the attending physician in order to achieve optimal fluid balance. Additionally, metabolic monitoring will be carried out by a blood ionogram every 12 hours. The quantitative parameters will be presented as median and interquartile range \[IQR\], and comparisons will be made using either Student's t-test or the Mann-Whitney U test depending on whether the assumptions of the t-test are met or not. Categorical data will be reported as the number and percentage (%) and will be compared using Fisher's exact or chi-square test, as appropriate. The incidence of filter clotting will be expressed in absolute values (n) and percentage (%). Comparison between groups will be performed using Pearson's Chi-square test. The analysis of the primary endpoint will be conducted on a per-protocol basis as a first intention (the most conservative approach in a non-inferiority study) and on an intention-to-treat basis. Filter lifespan until clotting curves according to the post-filter iCa2 target will be plotted using the Kaplan-Meier method and compared using the log-rank test.